Shares of Merck & Co. (MRK) rose 5% on Friday after the pharmaceutical giant reported positive developments across multiple ...

Keytruda is an immunotherapy drug that is prescribed to cancer patients and is used to treat different types of cancer. It was first approved by the FDA in 2014 for the treatment of advanced or ...

Treatment with the TROP2 ADC sac-TMT led to a 70% objective response rate and progression-free survival was “significantly ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive ...

Merck (MRK) stock gains as a cancer drug the company develops with Kelun-Biotech bests its Keytruda blockbuster in a ...

Summit Therapeutics (SMMT) stock faced a downgrade at H.C. Wainwright after late-stage trial data for Merck’s (MRK) lung cancer drug sac-TMT. Read more here.

Moderna and Merck's combination therapy for skin cancer helped reduce risk of cancer spreading to another part of the body ...

Merck narrowed its 2026 sales guidance and hiked its adjusted profit outlook.

This synergistic rationale drove the two-part structure of Toragen’s Phase 1 trial, with monotherapy in Part 1 and ...

Sichuan Kelun-Biotech Biopharmaceutical said on Thursday its experimental treatment combined with partner Merck's Keytruda ...

AstraZeneca’s first foray with PD-L1 inhibitor Imfinzi as a treatment for bladder cancer was a flop. | Following an FDA ...